138 related articles for article (PubMed ID: 38801852)
1. A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention.
Yan Y; Dai T; Guo M; Zhao X; Chen C; Zhou Y; Qin M; Xu L; Zhao J
Int J Biol Macromol; 2024 Jun; 271(Pt 2):132686. PubMed ID: 38801852
[TBL] [Abstract][Full Text] [Related]
2. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
[TBL] [Abstract][Full Text] [Related]
3. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
Wang W; Shen T; Dong B; Creighton CJ; Meng Y; Zhou W; Shi Q; Zhou H; Zhang Y; Moore DD; Yang F
J Clin Invest; 2019 Mar; 129(3):1015-1029. PubMed ID: 30688659
[TBL] [Abstract][Full Text] [Related]
4. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas.
He J; Huang Z; He M; Liao J; Zhang Q; Wang S; Xie L; Ouyang L; Koeffler HP; Yin D; Liu A
Mol Cancer; 2020 Jan; 19(1):17. PubMed ID: 31992303
[TBL] [Abstract][Full Text] [Related]
5. Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy.
Han D; Wang W; Jeon JH; Shen T; Huang X; Yi P; Dong B; Yang F
PLoS Biol; 2023 Aug; 21(8):e3002227. PubMed ID: 37531320
[TBL] [Abstract][Full Text] [Related]
6. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
[TBL] [Abstract][Full Text] [Related]
7. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
[TBL] [Abstract][Full Text] [Related]
8. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.
Wang W; Han D; Cai Q; Shen T; Dong B; Lewis MT; Wang R; Meng Y; Zhou W; Yi P; Creighton CJ; Moore DD; Yang F
Nat Commun; 2022 Jan; 13(1):245. PubMed ID: 35017531
[TBL] [Abstract][Full Text] [Related]
9. Identification of atypical mitogen-activated protein kinase MAPK4 as a novel regulator in acute lung injury.
Mao L; Zhou Y; Chen L; Hu L; Liu S; Zheng W; Zhao J; Guo M; Chen C; He Z; Xu L
Cell Biosci; 2020; 10():121. PubMed ID: 33088477
[TBL] [Abstract][Full Text] [Related]
10. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways.
Brouxhon SM; Kyrkanides S; Teng X; Raja V; O'Banion MK; Clarke R; Byers S; Silberfeld A; Tornos C; Ma L
Clin Cancer Res; 2013 Jun; 19(12):3234-46. PubMed ID: 23620408
[TBL] [Abstract][Full Text] [Related]
12. 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.
Lu Z; Cox-Hipkin MA; Windsor WT; Boyapati A
Mol Cancer Res; 2010 Mar; 8(3):421-32. PubMed ID: 20197379
[TBL] [Abstract][Full Text] [Related]
13. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
[TBL] [Abstract][Full Text] [Related]
14. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
15. SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
Bao F; An S; Yang Y; Xu TR
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107587
[TBL] [Abstract][Full Text] [Related]
16. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
18. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
19. Vernodalin Suppresses Tumor Proliferation and Increases Apoptosis of Gastric Cancer Cells Through Attenuation of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways.
Luo Y; Zhang D; Hou L; Lin N
Curr Pharm Biotechnol; 2023; 24(5):708-717. PubMed ID: 35909270
[TBL] [Abstract][Full Text] [Related]
20. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E; Pastuszak-Lewandoska D
Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
